Amphotericin B and lysine acetylsalicylate in the combined treatment of nasal polyposis associated with mycotic infection
Corradini, C.; Del Ninno, M.; Buonomo, A.; Nucera, E.; Paludetti, G.; Alonzi, C.; Sabato, V.; Schiavino, D.; Patriarca, G.
Journal of Investigational Allergology and Clinical Immunology 16(3): 188-193
2006
ISSN/ISBN: 1018-9068 PMID: 16784013 Document Number: 601516
Objective: To evaluate the effectiveness of a combined treatment with lysine acetylsalicylate (LAS) and amphotericin B in preventing recurrence in patients with nasal polyposis with accompanying mycotic infection, in comparison with a control group with nasal polyposis and fungal infection who did not receive antifungal therapy. Patients and Methods: 115 patients with nasal polyposis in the ENT and Allergy Departments, Catholic University of the Sacred Heart, Rome, Italy, were randomly assigned to 4 different treatment groups: (1) group A, 25 patients, were first surgically treated and then treated with LAS; (2) group B, 25 patients, received 40 mg of triamcinolone retard intramuscularly 3 times every 10 days (total dose 120 mg) and were then treated with LAS; (3) group C, 16 patients, were surgically treated and then treated with LAS and amphotericin B; (4) group D: 23 patients, were treated with a medical polypectomy and steroids (as in group B) and then with LAS and amphotericin B. Results: There were no significant differences between groups C and D, groups C and A, or groups B and D. However, the recurrence of nasal polyps in the groups treated with amphotericin B plus LAS (C and D) was significantly lower (P=0.018) than in the 2 groups treated only with LAS (A and B). Conclusion: Long term topical treatment with LAS and amphotericin B may be clinically effective in the treatment of patients with nasal polyposis associated with fungal infection.